Search Results - "Kuroishi, Kentarou"

Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post-marketing study by Katoh, Takao, Kuwamoto, Kana, Kato, Daisuke, Kuroishi, Kentarou

“…Objectives To assess the effect of 25 or 50 mg mirabegron on cardiovascular end‐points and adverse drug reactions in real‐world Japanese patients with…”
Get full text

Long‐Term Safety and Efficacy of Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis by Akizawa, Tadao, Tsukada, Junko, Kameoka, Chisato, Kuroishi, Kentarou, Yamaguchi, Yusuke

“…Bixalomer, a metal‐free, nonabsorbable phosphate binder, is approved in Japan to treat hyperphosphatemia in dialysis patients. Bixalomer is effective and has a…”
Get full text

Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial by Akizawa, Tadao, Origasa, Hideki, Kameoka, Chisato, Tsukada, Junko, Kuroishi, Kentarou, Yamaguchi, Yusuke

“…Currently, calcium‐ or metal‐containing phosphate binders are available to treat hyperphosphatemia in predialysis patients with chronic kidney disease…”
Get full text

Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a [beta]3-adrenoceptor agonist, in patients with overactive bladder in Asia by Kuo, Hann-Chorng, Lee, Kyu-Sung, Na, Yanqun, Sood, Rajeev, Nakaji, Shigeru, Kubota, Yosuke, Kuroishi, Kentarou

“…Aims To assess the efficacy and safety of mirabegron 50mg once daily compared with placebo and the active control, tolterodine extended-release (ER) 4mg once…”
Get full text

Safety and efficacy of mirabegron as ‘add‐on’ therapy in patients with overactive bladder treated with solifenacin: a post‐marketing, open‐label study in Japan (MILAI study) by Yamaguchi, Osamu, Kakizaki, Hidehiro, Homma, Yukio, Igawa, Yasuhiko, Takeda, Masayuki, Nishizawa, Osamu, Gotoh, Momokazu, Yoshida, Masaki, Yokoyama, Osamu, Seki, Narihito, Okitsu, Akira, Hamada, Takuya, Kobayashi, Akiko, Kuroishi, Kentarou

“…Objective To examine the safety and efficacy of mirabegron as ‘add‐on’ therapy to solifenacin in patients with overactive bladder (OAB). Patients and Methods…”
Get full text

Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia by Kuo, Hann-Chorng, Lee, Kyu-Sung, Na, Yanqun, Sood, Rajeev, Nakaji, Shigeru, Kubota, Yosuke, Kuroishi, Kentarou

“…Aims To assess the efficacy and safety of mirabegron 50 mg once daily compared with placebo and the active control, tolterodine extended‐release (ER) 4 mg once…”
Get full text

Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real‐World Clinical Setting: A Japanese Post‐Marketing Study by NOZAWA, Yumiko, KATO, Daisuke, TABUCHI, Hiromi, KUROISHI, Kentarou

“…Objectives To provide real‐world data on Japanese patients with overactive bladder (OAB) initiating treatment with the β3‐adrenoceptor agonist, mirabegron…”
Get full text

Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post‐marketing study by Yoshida, Masaki, Nozawa, Yumiko, Kato, Daisuke, Tabuchi, Hiromi, Kuroishi, Kentarou

“…Objectives A 12‐week post‐marketing study was conducted to provide real‐world data on Japanese patients with overactive bladder (OAB) initiating treatment with…”
Get full text

Tu1627 - Linaclotide is Effective and Safe for Patients with Chronic Constipation in Japan: A Phase III Randomized, Double-Blind, Placebo-Controlled Study with a Long-Term Open-Label Extension Study by Fukudo, Shin, Miwa, Hiroto, Nakajima, Atsushi, Kinoshita, Yoshikazu, Kosako, Masanori, Hayashi, Kenta, Akiho, Hikaru, Kuroishi, Kentarou, Johnston, Jeffrey M., Currie, Mark, Ohkusa, Toshifumi

Get full text

Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75years: Analysis of a Japanese post‐marketing study by Yoshida, Masaki, Nozawa, Yumiko, Kato, Daisuke, Tabuchi, Hiromi, Kuroishi, Kentarou

“…ObjectivesA 12‐week post‐marketing study was conducted to provide real‐world data on Japanese patients with overactive bladder (OAB) initiating treatment with…”
Get full text

Su1543 - Dose-Finding of Linaclotide for Patients with Chronic Constipation in Japan: A Phase II Randomized, Double-Blind, and Placebo-Controlled Study by Fukudo, Shin, Miwa, Hiroto, Nakajima, Atsushi, Kinoshita, Yoshikazu, Kosako, Masanori, Nakagawa, Ayako, Akiho, Hiraku, Kuroishi, Kentarou, Johnston, Jeffrey M., Currie, Mark, Ohkusa, Toshifumi

Get full text

Dose-Finding of Linaclotide for Patients with Chronic Constipation in Japan: A Phase II Randomized, Double-Blind, and Placebo-Controlled Study by Fukudo, Shin, Miwa, Hiroto, Nakajima, Atsushi, Kinoshita, Yoshikazu, Kosako, Masanori, Nakagawa, Ayako, Akiho, Hiraku, Kuroishi, Kentarou, Johnston, Jeffrey M, Currie, Mark, Ohkusa, Toshifumi

Get full text

Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real‐World Clinical Setting: A J apanese Post‐Marketing Study by NOZAWA, Yumiko, KATO, Daisuke, TABUCHI, Hiromi, KUROISHI, Kentarou

Get full text